MAPK1

Mitogen-activated protein kinase 1 · P28482 · MAPK1 on Sugi Atlas →

2,811,676 patent compounds predicted against MAPK1, 1,660,649 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL5531	0.50	7/20
Daunorubicin (SCHEMBL3041)	1.00	6/20
Idarubicin (SCHEMBL4838)	0.98	6/20
Carubicin (SCHEMBL4201)	0.85	6/20
Phenazopyridine (SCHEMBL270)	0.77	6/20
Idarubicin (SCHEMBL3750)	1.00	5/20
Desoxycorticosterone (SCHEMBL4065)	1.00	5/20
Desoxycorticosterone (SCHEMBL4066)	1.00	5/20
Daunorubicin (SCHEMBL4444)	1.00	5/20
Daunorubicin (SCHEMBL4445)	1.00	5/20
Colforsin (SCHEMBL4928)	1.00	5/20
Zorubicin (SCHEMBL4023)	0.80	5/20
Zorubicin (SCHEMBL4024)	0.80	5/20
Pentachlorophenol (SCHEMBL1492)	0.44	5/20
Hematoxylin (SCHEMBL1747)	1.00	4/20
Norepinephrine (SCHEMBL2609)	1.00	4/20
L-Norepinephrine (SCHEMBL2610)	1.00	4/20
Mitoxantrone (SCHEMBL3000)	1.00	4/20
Epirubicin (SCHEMBL3165)	1.00	4/20
Doxorubicin (SCHEMBL3242)	1.00	4/20

Clinical trials — most relevant to MAPK1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma	PHASE4	UNKNOWN
Clinical Evaluation of the Effect of Metformin in Sepsis	PHASE3	UNKNOWN
Anti-oxidative Influence From Pomegranate Tablets on Male Sperm Quality in Couples Undergo Infertility Treatments Due to Male Infertility.	PHASE3	UNKNOWN
Dabrafenib + Trametinib + PDR001 In Colorectal Cancer	PHASE2	UNKNOWN
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma	PHASE2	UNKNOWN
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma	PHASE1/PHASE2	COMPLETED
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma	PHASE1/PHASE2	COMPLETED
Study of Sorafenib and Infusional 5-Fluorouracil in Advanced Hepatocellular Carcinoma (HCC)	PHASE2	COMPLETED
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.	PHASE2	UNKNOWN
Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	PHASE2	COMPLETED
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations	PHASE2	ACTIVE_NOT_RECRUITING
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Study of ASTX029 in Subjects With Advanced Solid Tumors	PHASE1/PHASE2	COMPLETED
Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia	PHASE1/PHASE2	RECRUITING
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)	PHASE2	ACTIVE_NOT_RECRUITING
Clinical Study on the Treatment of Type I Neurofibromatosis With Smeitinib Hydrosulfate Capsule	PHASE2	NOT_YET_RECRUITING
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations	PHASE2	RECRUITING
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma	PHASE1	COMPLETED
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer	PHASE1	COMPLETED
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212	PHASE1	COMPLETED
BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)	PHASE1	COMPLETED
Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies	PHASE1	RECRUITING
Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia	PHASE1	RECRUITING
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo	nan	UNKNOWN
p38 Mitogen-Activated Protein Kinase (MAPK) and Steroid Insensitivity in Asthma	nan	COMPLETED
Histiocytic Disorder Follow-up Study	nan	RECRUITING
BRAF V600-mutated Lung Carcinoma Treated With the Combination of Dabrafenib-trametinib: a Retrospective Evaluation	nan	COMPLETED
Blood Flow Responses to an Oral Glucose Tolerance Test in Type 2 Diabetes	nan	COMPLETED
Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing	nan	RECRUITING
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a MAPK1 binder may also engage these)

Protein	Name	Similarity
P63086	—	1.000	P63086 →
P63085	—	1.000	P63085 →
P46196	—	0.998	P46196 →
P26696	—	0.997	P26696 →
P21708	—	0.994	P21708 →
G9MQI4	—	0.994	G9MQI4 →
A0A423WA64	—	0.994	A0A423WA64 →
MAPK3	Mitogen-activated protein kinase 3	0.992	landscape →
Q00859	—	0.992	Q00859 →
G4N0Z0	—	0.992	G4N0Z0 →
O42781	—	0.992	O42781 →
Q92246	—	0.991	Q92246 →
G1XJZ4	—	0.991	G1XJZ4 →
Q6Z437	—	0.991	Q6Z437 →
Q09892	—	0.990	Q09892 →
Q0U4L8	—	0.990	Q0U4L8 →
A0A5B9GBF0	—	0.989	A0A5B9GBF0 →
Q52PH6	—	0.989	Q52PH6 →
Q63844	—	0.989	Q63844 →
Q336X9	—	0.989	Q336X9 →
Q4PC06	—	0.989	Q4PC06 →
P40417	—	0.989	P40417 →
Q4W6D3	—	0.988	Q4W6D3 →
Q5Z859	—	0.988	Q5Z859 →
Q8TGA9	—	0.988	Q8TGA9 →
Q0D0P5	—	0.988	Q0D0P5 →
Q5I6M2	—	0.987	Q5I6M2 →
A1IVT7	—	0.987	A1IVT7 →
B0Y8W7	—	0.987	B0Y8W7 →
B0XR80	—	0.987	B0XR80 →